CanSino Biologics Inc.

6185

CNE100003F01

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
18.82 ^HKD	+2.51%		+14.06%	-20.08%

Apr. 22	Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	MT
Apr. 22	Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	MT

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

January 30, 2024 at 06:10 am EST

CanSino Biologics Inc. provided earnings guidance for year ended December 31, 2023. For the year, company expects net loss attributable to the shareholders of the Company to be RMB 1,268.5 million to RMB 1,496.9 million.

Latest news about CanSino Biologics Inc.

Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	Apr. 22	MT
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	Apr. 21	MT
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	Mar. 20	MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	Mar. 20	CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	Mar. 14	MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	Feb. 28	CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	Feb. 26	MT
Cansino Biologics Inc. Announces Board and Committee Elections	Feb. 23	CI
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
CanSino Biologics Deconsolidates CanSino SPH	Feb. 02	MT
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	Jan. 31	MT
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	Jan. 31	MT
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	Jan. 30	CI
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	Jan. 30	CI
CanSino Biologics Enrols First Patient in Australia Clinical Trial of Polio Vaccine	Jan. 15	MT
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	Jan. 15	CI
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	Jan. 12	MT
CanSino Biologics Enrolls First Patient in Tetanus Vaccine Trial	Dec. 20	MT
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	Dec. 20	CI
Scientists see risk of lost opportunity for long COVID research in China	Dec. 13	RE
CanSino Biologics Inc.(SHSE:688185) dropped from Shanghai Stock Exchange Health Care Sector Index	Dec. 08	CI
CanSino Biologics Begins Phase 1 Trials for TDCP Vaccine in China	Dec. 07	MT
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	Dec. 06	CI
CanSino Biologics' COVID-19 Vaccine Included for China's Emergency Use	Dec. 04	MT
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	Dec. 03	CI

Chart CanSino Biologics Inc.

Duration

Period

More charts

Company Profile

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 06:08 am EDT

More Strategies

Ratings for CanSino Biologics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.42 CNY

Average target price

24.32 CNY

Spread / Average Target

+39.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CANSINO BIOLOGICS INC.	-20.08%	1.1B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals